Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
OMS
MCID: OTT002
MIFTS: 72

Otitis Media (OMS)

Categories: Ear diseases, Genetic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Otitis Media

About this section

MalaCards integrated aliases for Otitis Media:

Name: Otitis Media 56 12 73 29 54 3 43 15 17 71
Otitis Media, Susceptibility to 56 29 6
Otitis Media, Chronic/recurrent 56 73
Come/rom 56 73
Oms 56 73
Otitis Media Susceptibility to 13
Infectious Otitis Media 71
Om 73

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
otitis media:
Inheritance autosomal dominant inheritance polygenic inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Ear diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:10754
OMIM 56 166760
ICD9CM 34 382.9
MeSH 43 D010033
NCIt 49 C34885
SNOMED-CT 67 65363002
ICD10 32 H66.9 H67 H67.8
MedGen 41 C1833692
SNOMED-CT via HPO 68 263681008
UMLS 71 C0029882 C2827407
Sources

Summaries for Otitis Media

About this section
CDC : 3 Ear infections can affect the ear canal or the middle ear. Acute otitis externa (AOE) is the scientific name for an infection of the ear canal, which is also called swimmer's ear. Middle ear infections are called Otitis Media, and there are two types of middle ear infections: Otitis Media with Effusion (OME) occurs when fluid builds up in the middle ear without pain, pus, fever, or other signs and symptoms of infection. Acute Otitis Media (AOM) occurs when fluid builds up in the middle ear and is often caused by bacteria, but can also be caused by viruses.

MalaCards based summary : Otitis Media, also known as otitis media, susceptibility to, is related to suppurative otitis media and mastoiditis. An important gene associated with Otitis Media is A2ML1 (Alpha-2-Macroglobulin Like 1), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Halofantrine and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and brain, and related phenotypes are recurrent otitis media and homeostasis/metabolism

Disease Ontology : 12 A otitis which involves inflammation of the middle ear.

UniProtKB/Swiss-Prot : 73 Otitis media: An inflammation of the middle ear resulting in earache, fever, hearing disturbance, and vertigo.

Wikipedia : 74 Otitis media is a group of inflammatory diseases of the middle ear. The two main types are acute otitis... more...

More information from OMIM: 166760
Sources

Related Diseases for Otitis Media

About this section

Diseases related to Otitis Media via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1176)
# Related Disease Score Top Affiliating Genes
1 suppurative otitis media 35.3 TLR4 TLR2 IL1B FBXO11 CRP CD40LG
2 mastoiditis 33.8 MUC5B CRP CD40LG
3 pharyngitis 33.3 TNF LACTB IL6 IL1B CXCL8 CRP
4 haemophilus influenzae 33.1 TNF TLR2 LACTB CXCL8
5 allergic rhinitis 32.1 RNASE3 IL10 CXCL8 CCL11
6 rhinitis 32.0 TNF TLR4 RNASE3 IL6 IL1B IL10
7 gastroesophageal reflux 31.9 TNF IL6 IL1B CXCL8 CCL11
8 influenza 31.9 TNF TLR4 IL6 IL1B CXCL8
9 bone resorption disease 31.8 TNF IL6 IL1B CRP
10 thrombophlebitis 31.7 TNF PLG CRP CD40LG
11 pleural empyema 31.6 PLG CRP CD79A CD40LG
12 diarrhea 31.6 TNF TLR4 IL6 IL1B IL10 CXCL8
13 conjunctivitis 31.6 TNF RNASE3 PLG IL6 IL10 CXCL8
14 dermatitis 31.6 TNF IL6 IL1B IL10 CXCL8 CCL11
15 tonsillitis 31.6 TNF TLR4 TLR2 LACTB IL6 IL1B
16 exanthem 31.6 TNF IL6 IL1B IL10 CXCL8 CRP
17 middle ear disease 31.6 TNF TLR4 TLR2 MUC5B MUC5AC IL6
18 vasculitis 31.6 TNF MBL2 IL6 IL10 CRP CD79A
19 allergic hypersensitivity disease 31.5 TNF RNASE3 IL10 CXCL8 CCL11
20 mycobacterium abscessus 31.5 TNF TLR2 CXCL8
21 meningitis 31.5 TNF TLR4 TLR2 MBL2 LACTB IL6
22 hypereosinophilic syndrome 31.5 RNASE3 IL10 CXCL8 CCL11
23 scarlet fever 31.5 TNF CRP CD40LG
24 food allergy 31.4 TNF TLR4 TLR2 RNASE3 IL10 CXCL8
25 bacterial infectious disease 31.4 TNF TLR4 TLR2 MBL2 IL6 IL1B
26 maxillary sinusitis 31.4 RNASE3 LACTB CRP CD40LG
27 osteomyelitis 31.4 TNF TLR4 TLR2 IL6 IL1B IL10
28 granulomatosis with polyangiitis 31.4 TNF TLR4 TLR2 CRP CD40LG
29 hepatitis a 31.3 TNF TLR4 IL1B IL10 CXCL8
30 sleep apnea 31.3 TNF IL6 IL1B IL10 CXCL8 CRP
31 tuberculous meningitis 31.3 TNF TLR2 CXCL8
32 spinal cord injury 31.3 TNF IL6 CXCL8
33 cellulitis 31.3 TNF RNASE3 IL6 IL1B IL10 CRP
34 common cold 31.2 TNF TLR4 TLR2 RNASE3 MUC5AC IL6
35 milk allergy 31.2 TNF RNASE3 IL10 CD79A
36 neuritis 31.2 TNF IL6 IL1B IL10 CXCL8
37 streptococcus pneumonia 31.2 TNF TLR4 TLR2 IL6 IL1B IL10
38 measles 31.2 TNF TLR4 TLR2 IL6 IL1B CXCL8
39 bacterial meningitis 31.2 TNF TLR4 TLR2 MBL2 LACTB IL6
40 septic arthritis 31.2 TNF TLR4 TLR2 IL6 IL1B CXCL8
41 bacterial conjunctivitis 31.2 IL1B CXCL8 CRP CD40LG
42 chlamydia pneumonia 31.2 TNF TLR4 TLR2 IL6 IL1B IL10
43 parotitis 31.2 CRP CD79A CD40LG
44 trachoma 31.2 TNF MBL2 IL6 IL10
45 pulmonary tuberculosis 31.2 TNF TLR4 TLR2 MBL2 IL6 IL1B
46 chlamydia 31.1 TNF TLR4 TLR2 MBL2 IL6 IL1B
47 mycobacterium fortuitum 31.1 LACTB CXCL8
48 mycobacterium chelonae 31.1 TLR2 CXCL8
49 immune deficiency disease 31.1 TNF TLR2 MBL2 IL6 IL10 CD79A
50 bronchiectasis 31.1 TNF TLR2 MBL2 IL1B CXCL8 CRP

Comorbidity relations with Otitis Media via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Cholesteatoma of Middle Ear Deficiency Anemia
Heart Disease Hypertension, Essential
Labyrinthitis Mastoiditis
Otitis Externa Pneumococcal Meningitis

Graphical network of the top 20 diseases related to Otitis Media:



Diseases related to Otitis Media
Sources

Symptoms & Phenotypes for Otitis Media

About this section

Human phenotypes related to Otitis Media:

31
# Description HPO Frequency HPO Source Accession
1 recurrent otitis media 31 HP:0000403

Symptoms via clinical synopsis from OMIM:

56
Head And Neck Ears:
otitis media

Clinical features from OMIM:

166760

MGI Mouse Phenotypes related to Otitis Media:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 CD40LG CD79A CRP FBXO11 IL10 IL1B
2 hematopoietic system MP:0005397 10.18 CCL11 CD40LG CD79A FBXO11 IL10 IL1B
3 cardiovascular system MP:0005385 10.13 CD40LG CRP IL10 IL1B IL6 LACTB
4 immune system MP:0005387 10.13 CCL11 CD40LG CD79A CRP FBXO11 IL10
5 digestive/alimentary MP:0005381 10.01 FBXO11 IL10 IL6 MUC5AC PLG TLR2
6 integument MP:0010771 9.81 CD40LG FBXO11 IL10 IL1B IL6 PLG
7 neoplasm MP:0002006 9.56 CD79A IL10 IL1B IL6 PLG TLR2
8 respiratory system MP:0005388 9.23 CCL11 IL10 IL6 MUC5B PLG TLR2
Sources

Drugs & Therapeutics for Otitis Media

About this section

Drugs for Otitis Media (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 213)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Halofantrine Approved Phase 4 69756-53-2 37393
2
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
5
Cefdinir Approved Phase 4 91832-40-5 6915944
6
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
7
Montelukast Approved Phase 4 158966-92-8 5281040
8
Azithromycin Approved Phase 4 83905-01-5 447043 55185
9
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
10
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
11
Histamine Approved, Investigational Phase 4 51-45-6 774
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
14
Levocetirizine Approved Phase 4 130018-77-8 1549000
15
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
16
Cefpodoxime Approved, Vet_approved Phase 4 80210-62-4, 82619-04-3 6335986
17
Phenylephrine Approved Phase 4 59-42-7 6041
18
Pseudoephedrine Approved Phase 4 90-82-4 7028
19
Ephedrine Approved Phase 4 299-42-3 9294
20
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
21 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
22
Cetirizine Approved Phase 4 83881-51-0 2678
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
24
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
25
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
26
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
27 Strawberry Approved Phase 4
28
Morphine Approved, Investigational Phase 4 57-27-2 5288826
29
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
30
Lumefantrine Approved Phase 4 82186-77-4 6437380
31
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
32
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
33
Artemether Approved Phase 4 71963-77-4 68911 9796294 119380
34
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
35
Ofloxacin Approved Phase 4 82419-36-1 4583
36
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
37
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
38
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
39
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
40
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
41
Propyl Gallate Investigational Phase 4 121-79-9 4947
42
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
43
BCG vaccine Investigational Phase 4
44 Analgesics, Non-Narcotic Phase 4
45 Anti-Inflammatory Agents, Non-Steroidal Phase 4
46 Ketorolac Tromethamine Phase 4
47 Citrate Phase 4
48 Cyclooxygenase Inhibitors Phase 4
49 Broncho-Vaxom Phase 4
50 Vaccines Phase 4

Interventional clinical trials:

(show top 50) (show all 336)
# Name Status NCT ID Phase Drugs
1 The Influence of The Ear Popper on Serous Otitis Media and on the Accompanying Conductive Hearing Loss in Children Unknown status NCT00393159 Phase 4
2 Phase 4 Efficacy Study of Antimicrobials in the Treatment of Acute Otitis Media in Young Children Unknown status NCT00299455 Phase 4 amoxicillin-clavulanate;Placebo
3 Prospective, Randomized, Allocation-Concealed, Blinded Study Designed to Compare Ketorolac Sublingual and Fentanyl Intranasal in Pain Control for Bilateral Myringotomy and Tubes (BMT) Placement in Children Unknown status NCT02653742 Phase 4 Ketorolac;Fentanyl
4 Effect of Vaxoral® (OM-85) on Frequency of Respiratory Tract Infections and Size of Adenoid Tissue in Preschool Children With Adenoid Hypertrophy Unknown status NCT03243565 Phase 4
5 Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Unknown status NCT00494624 Phase 4 prednisolone
6 A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children Completed NCT00189462 Phase 4 Montelukast
7 Amoxycillin Versus Placebo for Resolution of Otitis Media With Effusion and Prevention of Acute Otitis Media With Perforation in Aboriginal Infants: a Randomised Controlled Trial. Completed NCT00539149 Phase 4 Amoxycillin;Placebo equivalent to amoxycillin
8 A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media Completed NCT00644943 Phase 4 cefdinir (Omnicef);amoxicillin
9 Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion (OME) Compared to That of Combination of Antibiotic, Antihistaminic, and Nasal Decongestant Completed NCT03590912 Phase 4 Mometasone 50 Mcg/Inh Nasal Spray;Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%);Steroid Drug (prednisolone)
10 A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media Completed NCT00645112 Phase 4 cefdinir (Omnicef);azithromycin
11 A Double-Blind, Randomized, Placebo-Controlled Study of Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age Completed NCT00593502 Phase 4 oseltamivir;placebo
12 A Randomised Controlled Trial of Pneumococcal Conjugate Vaccines Synflorix and Prevenar13 in Sequence or Alone in High-risk Indigenous Infants (PREV-IX_COMBO): Immunogenicity, Carriage and Otitis Media Outcomes Completed NCT01174849 Phase 4 Synflorix;Prevenar13;COMBO
13 Evaluation of the Effects of Enterogermina, 2 Billion Bacillus Clausii Spores, on the Intestinal Flora of Children Antibiotic Treated for Bacterial Upper Respiratory Tract Infections: Open, Pilot Study. Completed NCT00424905 Phase 4 Bacillus clausii
14 Efficacy of Antimicrobials in Young Children With Acute Otitis Media (AOM) Completed NCT00377260 Phase 4 amoxicillin-clavulanate;Placebo
15 Role of Empiric Anti-reflux Therapy in Pediatric Otitis Media With Effusion - a Pilot Study Completed NCT01082029 Phase 4 Lansoprazole;Placebo
16 Postoperative Analgesic and Behavioral Effects of Intranasal Fentanyl, Intravenous Morphine and Intramuscular Morphine in Pediatric Patients Undergoing Bilateral Myringotomy and Placement of Ventilating Tubes Completed NCT01244126 Phase 4 Intranasal fentanyl;morphine IM;IV morphine
17 Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®) Completed NCT00419380 Phase 4 dornase alfa (Pulmozyme®)
18 Role of Montelukast in Asthma and Allergic Rhinitis Patients Completed NCT03380975 Phase 4 Montelukast 10mg
19 Does Vaccinating Health Hutterite Children Against Influenza Prevent Influenza in Other Hutterite Colony Members: A Randomized Cluster Trial Completed NCT00877396 Phase 4
20 Comparison of the Immunogenicity of the 3+1 Schedule and the 2+1 Schedule of 7-valent Pneumococcal Conjugated Vaccine in Young Chinese Infants Completed NCT02040402 Phase 4
21 A Multi-Center, Open-Label Study Evaluating Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Enzyme Replacement Therapy Completed NCT00607386 Phase 4
22 Clinical Trial for the Assessment of Delayed Antibiotic Treatment in the Non-complicated Acute Respiratory Tract Infections in Pediatric (Study DAP-Pediatrics) Completed NCT01800747 Phase 4
23 Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Controlled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive and Mucosal Infections. Completed NCT01735084 Phase 4
24 A Randomized Controlled Trial of Live Attenuated Vaccine Versus Trivalent Inactivated Vaccine in Hutterite Children Completed NCT01653015 Phase 4
25 Comparison of Postoperative Infection and Graft Uptake Rate Using Single Dose of Intravenous Co-amoxiclav Versus no Antibiotic in Children Undergoing Myringoplasty Completed NCT03700814 Phase 4 Co-amoxiclav
26 Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric Completed NCT02617771 Phase 4 Vitamin D3
27 Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. A Prospective, Randomised, Clinical Trial. Completed NCT01694108 Phase 4
28 TEAM (Trial on Efficacy and Quality of Life Among Asthmatic Patient With Montelukast) Completed NCT03096327 Phase 4 Montelukast;Placebo
29 A Phase IV, Single Group Study to Evaluate the Immunogenicity and Safety in UK Laboratory Workers of a Licensed Hib and Meningococcal C Conjugate Combined Vaccine (Menitorix) Completed NCT00503165 Phase 4
30 In Vivo Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria: an Open-randomised, Non-inferiority Clinical Trial in South Kivu, DR Congo Completed NCT02741024 Phase 4 Amodiaquine-Artesunate (ASAQ);Artemether-Lumefantrine (AL)
31 Effect of Antimicrobial Treatment of Acute Otitis Media on the Intestinal Microbiome in Children: A Randomized Controlled Trial Recruiting NCT02935374 Phase 4 Amoxicillin;Amoxicillin-Potassium Clavulanate;Macrolide
32 Does the Use of Topical Otic Drops at the Time of Tympanostomy Tube Placement Improve Outcomes When no Middle Ear Effusion is Present at the Time of Surgery Not yet recruiting NCT03655665 Phase 4 Ofloxacin otic solution
33 N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media Withdrawn NCT00956748 Phase 4 Ciprodex;Ciprodex and 2% NAC
34 Otiprio Versus Ciprodex to Reduce Tympanostomy Tube Failure Withdrawn NCT03347461 Phase 4 Otiprio;Ciprodex
35 A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux Withdrawn NCT01308502 Phase 4
36 A Randomized Control Study of the Outcomes of Mastoidotympanoplasty Versus Tympanoplasty in Quiescent Tubotympanic Otitis Media Unknown status NCT00271778 Phase 3
37 PneuMum: A Randomised Controlled Trial of Pneumococcal Polysaccharide Vaccination for Aboriginal and Torres Strait Islander Mothers to Protect Their Babies From Ear Disease Unknown status NCT00310349 Phase 3
38 A Study of Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines to Inform Policy Regarding Pneumococcal Vaccination of Papua New Guinean Children Unknown status NCT01619462 Phase 3
39 Reducing Disease Burden and Health Inequalities Arising From Chronic Dental Disease Among Indigenous Children: an Early Childhood Caries Intervention Unknown status NCT02151916 Phase 3
40 A Clinical Study of the Acclarent Tympanostomy Tube Delivery System for the Treatment of Patients Requiring Tympanostomy Tube Insertion for Otitis Media Completed NCT01202578 Phase 2, Phase 3
41 Safety and Efficacy of EXE844 Otic Suspension in the Treatment of Otitis Media at Time of Tympanostomy Tube Insertion Completed NCT02436304 Phase 3 EXE844 Sterile Otic Suspension, 0.3%
42 Safety and Efficacy of EXE844 Otic Suspension in the Treatment of Otitis Media at Time of Tympanostomy Tube Insertion Completed NCT02432105 Phase 3 EXE844 Sterile Otic Suspension, 0.3%
43 An Open-Label, Safety and Efficacy Study of Cefdinir Oral Suspension, 25 mg/kg Once Daily, in Pediatric Subjects With Acute Otitis Media Completed NCT00645203 Phase 2, Phase 3 cefdinir
44 Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children Completed NCT02541760 Phase 3 Monteleukast;Mometasone
45 Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children Completed NCT01044030 Phase 3 Xylitol syrup;Placebo
46 A Randomized, Multicenter, Comparative Study To Assess Tolerability Of A Single Oral 60 Mg/Kg Dose Of Zmax (Pediatric Concentration) Vs. Zmax (Adult Concentration) In Pediatric Patients With Acute Otitis Media Completed NCT00360100 Phase 3 Zmax
47 An 8-Week, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes Completed NCT02600559 Phase 3 OTO-201 (ciprofloxacin)
48 Oral Amoxicillin-clavulanate in Treating Acute Otitis Media in Children: Randomized Double-blind Placebo-controlled Study Including Daily Monitoring With Tympanometry Completed NCT01244581 Phase 3 Amoxicillin-clavulanate;Placebo
49 Evaluation of the Safety, Efficacy, Pharmacokinetics, and Acceptability of HMR3647 20 mg/kg qd for 5 Days With Acute Otitis Media (AOM) in Children (Multicenter, Open Label, Non Comparative Study) Completed NCT00638534 Phase 3 Telithromycin (HMR3647)
50 Acute Otitis Media: Adjuvant Therapy to Improve Outcome Completed NCT00000363 Phase 3 Antihistamine;Corticosteroid

Search NIH Clinical Center for Otitis Media

Inferred drug relations via UMLS 71 / NDF-RT 50 :


acetyl sulfisoxazole
Antipyrine
Benzocaine
BENZOCAINE PWDR
CEFTIBUTEN DIHYDRATE
Sulfisoxazole
Sulfisoxazole Diolamine

Cochrane evidence based reviews: otitis media

Sources

Genetic Tests for Otitis Media

About this section

Genetic tests related to Otitis Media:

# Genetic test Affiliating Genes
1 Otitis Media 29
2 Otitis Media, Susceptibility to 29 A2ML1
Sources

Anatomical Context for Otitis Media

About this section

MalaCards organs/tissues related to Otitis Media:

40
Bone, Testes, Brain, Colon, Tonsil, Neutrophil, Breast
Sources

Publications for Otitis Media

About this section

Articles related to Otitis Media:

(show top 50) (show all 20491)
# Title Authors PMID Year
1
Genetic and Environmental Determinants of Otitis Media in an Indigenous Filipino Population. 56 6 61
27484237 2016
2
Rare A2ML1 variants confer susceptibility to otitis media. 56 61
26121085 2015
3
Eya4-deficient mice are a model for heritable otitis media. 61 56
18219393 2008
4
Chronic and recurrent otitis media: a genome scan for susceptibility loci. 56 61
15514890 2004
5
The heritability of otitis media: a twin and triplet study. 56 61
10591333 1999
6
Susceptibility to otitis media: strong evidence that genetics plays a role. 56 61
10591340 1999
7
Familial predisposition for otitis media in Apache Indians at Canyon Day, Arizona. 61 56
3569876 1987
8
Mucin gene polymorphisms in otitis media patients. 61 54
19718741 2010
9
[Evaluation of percentage of lymphocytes B with expression of co-receptors CD 40, CD22 and CD72 in hypertrophied adenoid at children with otitis media with effusion]. 61 54
20198985 2009
10
Glucocorticoids inhibit nontypeable Haemophilus influenzae-induced MUC5AC mucin expression via MAPK phosphatase-1-dependent inhibition of p38 MAPK. 61 54
18957283 2008
11
Toll-like receptors 2 and 4 and their mutations in patients with otitis media and middle ear effusion. 54 61
19434266 2008
12
Antibodies to pneumococcal surface protein A families 1 and 2 in serum and saliva of children and the risk of pneumococcal acute otitis media. 54 61
18008233 2007
13
Association of CD14 promoter polymorphism with otitis media and pneumococcal vaccine responses. 61 54
16893989 2006
14
Functional polymorphisms in the mannan-binding lectin 2 gene: effect on MBL levels and otitis media. 54 61
16750996 2006
15
[The measuring of ECP and IgE in middle ear effusion of patients with otitis media of effusion]. 54 61
16883790 2006
16
Total serum IgE and IgE antibodies specific to house dust mite found in two aged-matched cohorts of children with and without otitis media with effusion. 61 54
16620332 2006
17
Up-regulation of MUC5AC and MUC5B mucin genes in nasopharyngeal respiratory mucosa and selective up-regulation of MUC5B in middle ear in pediatric otitis media with effusion. 61 54
16540890 2006
18
Role of mannose-binding lectin (MBL2) genotyping in predicting the risk of recurrent otitis media (rOM). 54 61
16893079 2006
19
Childhood levels of immunoglobulins and mannan-binding lectin in relation to infections and allergy. 54 61
15882439 2005
20
Immunological status in the aetiology of recurrent otitis media with effusion: serum immunoglobulin levels, functional mannose-binding lectin and Fc receptor polymorphisms for IgG. 54 61
15742161 2005
21
Immunological parameters in girls with Turner syndrome. 61 54
15563731 2004
22
IL-5 and eotaxin levels in middle ear effusion and blood from asthmatics with otitis media with effusion. 61 54
12737295 2003
23
Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase. 54 61
11867630 2002
24
Human lactoferrin proteolytic activity: analysis of the cleaved region in the IgA protease of Haemophilus influenzae. 54 61
11163480 2000
25
Increased expression of major basic protein (MBP) and interleukin-5(IL-5) in middle ear biopsy specimens from atopic patients with persistent otitis media with effusion. 54 61
11077335 2000
26
[Immunology in the medical practice. XXVII. Mannose-binding lectin, an important link for nonspecific or hereditary immune reaction]. 61 54
10897301 2000
27
Eosinophils and neutrophils in biopsies from the middle ear of atopic children with otitis media with effusion. 61 54
10669113 1999
28
The influence of karyotype on the auricle, otitis media and hearing in Turner syndrome. 54 61
10575123 1999
29
Evidence of possible localized specific immunoglobulin E production in middle ear fluid as demonstrated by ELISA testing. 54 61
10471862 1999
30
Microbial factors leading to recurrent upper respiratory tract infections. 61 54
9727652 1998
31
Eosinophil cationic protein in mucosal biopsies from patients with allergy and otitis media with effusion. 61 54
9230321 1997
32
Association of otitis media with effusion and allergy as demonstrated by intradermal skin testing and eosinophil cationic protein levels in both middle ear effusions and mucosal biopsies. 54 61
8822719 1996
33
Levels of eosinophil cationic protein and myeloperoxidase from chronic middle ear effusion in patients with allergy and/or acute infection. 61 54
8643262 1996
34
Mannan-binding protein--levels in plasma and upper-airways secretions and frequency of genotypes in children with recurrence of otitis media. 61 54
8403525 1993
35
The presence of eosinophil cationic protein in middle ear effusion. 54 61
8516010 1993
36
Correlation between serum immunoglobulin A concentrations and allergic manifestations in infants. 61 54
1625088 1992
37
Sulbactam/ampicillin in the treatment of otitis and sinusitis. 54 61
2060691 1991
38
The role of bacterial adherence in otitis media with effusion. 54 61
2206498 1990
39
Prospective study about the incidence of B lactamase producing bacteriae in otitis media in the population of the emergency room of the University Pediatric Hospital. 54 61
2375816 1990
40
The results of hearing screening in refugee school children living in Åžanliurfa /Turkey and the related risk factors. 61
32289664 2020
41
Alternative therapy to manage otitis media caused by multidrug-resistant fungi. 61
32108246 2020
42
The change of prevalence and recurrence of acute otitis media in Korea. 61
32272374 2020
43
Impact of early gastroesophageal reflux disease on childhood otologic outcomes. 61
32371356 2020
44
A core outcome set for research on the management of otitis media with effusion in otherwise-healthy children. 61
32272377 2020
45
Middle ear disease in CF? It's not just about the sinuses anymore! 61
32259649 2020
46
The biofilm-associated bacterial infections unrelated to indwelling devices. 61
32150327 2020
47
First report on multidrug-resistant non-encapsulated Streptococcus pneumoniae isolated from a patient with pneumonia. 61
32409019 2020
48
The microbiomes of adenoid and middle ear in children with otitis media with effusion and hypertrophy from a tertiary hospital in China. 61
32388082 2020
49
Exploring metabolic adaptation of Streptococcus pneumoniae to antibiotics. 61
32210362 2020
50
A bench-top model of middle ear effusion diagnosed with optical tympanometry. 61
32344235 2020
Sources

Variations for Otitis Media

About this section

ClinVar genetic disease variations for Otitis Media:

6 (show all 24) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 A2ML1 NM_144670.6(A2ML1):c.4061+1G>CSNV Pathogenic 617554 rs202067416 12:9020954-9020954 12:8868358-8868358
2 A2ML1 NM_144670.6(A2ML1):c.2478_2485dup (p.Ser829fs)duplication Pathogenic,risk factor 217306 rs863224951 12:9004818-9004819 12:8852222-8852223
3 PLG NM_001168338.1(PLG):c.112A>G (p.Lys38Glu)SNV Pathogenic/Likely pathogenic 13583 rs73015965 6:161127501-161127501 6:160706469-160706469
4 A2ML1 NM_144670.6(A2ML1):c.10C>T (p.Gln4Ter)SNV Likely pathogenic 617555 rs1409944554 12:8975257-8975257 12:8822661-8822661
5 A2ML1 NM_144670.6(A2ML1):c.4061+1G>ASNV Conflicting interpretations of pathogenicity 696412 12:9020954-9020954 12:8868358-8868358
6 A2ML1 NM_144670.6(A2ML1):c.2713-8C>ASNV Conflicting interpretations of pathogenicity 241896 rs184386564 12:9007368-9007368 12:8854772-8854772
7 A2ML1 NM_144670.6(A2ML1):c.2197T>C (p.Phe733Leu)SNV Conflicting interpretations of pathogenicity 384690 rs117213221 12:9002833-9002833 12:8850237-8850237
8 PLG NM_000301.3(PLG):c.2045T>A (p.Ile682Asn)SNV Uncertain significance 692203 rs147175166 6:161162369-161162369 6:160741337-160741337
9 A2ML1 NM_144670.6(A2ML1):c.2677C>T (p.Arg893Ter)SNV Uncertain significance 217310 rs199651558 12:9006810-9006810 12:8854214-8854214
10 A2ML1 NM_144670.6(A2ML1):c.971-8C>TSNV Uncertain significance 617556 rs780868782 12:8991701-8991701 12:8839105-8839105
11 A2ML1 NM_144670.6(A2ML1):c.1308A>C (p.Gln436His)SNV Uncertain significance 617557 rs780743143 12:8995789-8995789 12:8843193-8843193
12 A2ML1 NM_144670.6(A2ML1):c.2012T>C (p.Leu671Pro)SNV Uncertain significance 617558 rs1465018225 12:9001494-9001494 12:8848898-8848898
13 A2ML1 NM_144670.6(A2ML1):c.2329G>A (p.Gly777Arg)SNV Uncertain significance 617559 rs201288888 12:9004474-9004474 12:8851878-8851878
14 A2ML1 NM_144670.6(A2ML1):c.2971G>C (p.Ala991Pro)SNV Uncertain significance 626344 rs1565484901 12:9009882-9009882 12:8857286-8857286
15 A2ML1 NM_144670.6(A2ML1):c.3491C>T (p.Ala1164Val)SNV Uncertain significance 626345 rs1565487941 12:9013882-9013882 12:8861286-8861286
16 A2ML1 NM_144670.6(A2ML1):c.164C>T (p.Thr55Ile)SNV Uncertain significance 626339 rs999028234 12:8975879-8975879 12:8823283-8823283
17 A2ML1 NM_144670.6(A2ML1):c.1683G>C (p.Gln561His)SNV Uncertain significance 626340 rs1565476223 12:8998818-8998818 12:8846222-8846222
18 A2ML1 NM_144670.6(A2ML1):c.2189G>A (p.Arg730His)SNV Uncertain significance 626341 rs200346409 12:9002825-9002825 12:8850229-8850229
19 A2ML1 NM_144670.6(A2ML1):c.2228C>T (p.Pro743Leu)SNV Uncertain significance 626342 rs1565479896 12:9002864-9002864 12:8850268-8850268
20 A2ML1 NM_144670.6(A2ML1):c.2545G>T (p.Asp849Tyr)SNV Uncertain significance 626343 rs1408810942 12:9004887-9004887 12:8852291-8852291
21 PLG NM_000301.3(PLG):c.782G>A (p.Arg261His)SNV Benign 692201 rs4252187 6:161137790-161137790 6:160716758-160716758
22 PLG NM_000301.3(PLG):c.1414G>A (p.Asp472Asn)SNV Benign 692202 rs4252125 6:161152240-161152240 6:160731208-160731208
23 PLG NM_000301.3(PLG):c.1481C>T (p.Ala494Val)SNV Benign 692204 rs4252128 6:161152819-161152819 6:160731787-160731787
24 A2ML1 NM_144670.6(A2ML1):c.3364C>T (p.Arg1122Trp)SNV Benign 384669 rs1860967 12:9013755-9013755 12:8861159-8861159
Sources

Expression for Otitis Media

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Otitis Media patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 PNLIPRP3 pancreatic lipase-related protein 3 Blood - 6.47 0.003
2 FAM20A family with sequence similarity 20, member A Blood + 3.09 0.015
Search GEO for disease gene expression data for Otitis Media.
Sources

Pathways for Otitis Media

About this section

Pathways related to Otitis Media according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.04 TNF TLR4 TLR2 RNASE3 MUC5B MUC5AC
2
Akt Signaling 63
Show member pathways
 13.48 TNF TLR4 TLR2 IL6 IL1B IL10
3
Cytokine Signaling in Immune system 65
Show member pathways
 13.38 TNF IL6 IL1B IL10 CXCL8 CD40LG
4
PAK Pathway 63
Show member pathways
 13.33 TNF IL6 IL1B IL10 CXCL8 CD40LG
5
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.12 TNF TLR4 TLR2 MBL2 IL6 IL1B
6
Human cytomegalovirus infection 36
Show member pathways
 12.98 TNF TLR4 TLR2 IL6 IL1B CXCL8
7
Allograft rejection 1 36
Show member pathways
 12.91 TNF RNASE3 IL6 IL1B IL10 CXCL8
8
Measles 36
Show member pathways
 12.89 TNF TLR4 TLR2 PLG IL6 IL1B
9
NF-KappaB Family Pathway 63
Show member pathways
 12.78 TNF TLR4 TLR2 IL6 IL1B CD40LG
10
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.77 TNF TLR4 TLR2 MUC5B MUC5AC IL6
11
T cell receptor signaling pathway 36
Show member pathways
 12.68 TNF TLR4 TLR2 IL6 IL1B IL10
12
Th17 cell differentiation 36
Show member pathways
 12.67 TNF TLR4 TLR2 IL6 IL1B IL10
13
Immune response IL-23 signaling pathway 22
Show member pathways
 12.64 TNF PLG IL6 IL1B IL10
14
NF-kappaB Signaling 4
12.64 TNF TLR2 IL1B IL10 CD79A CD40LG
15
TRAF Pathway 63
Show member pathways
 12.63 TNF TLR4 TLR2 IL1B CD40LG
16
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.42 TNF IL6 IL10 CXCL8 CCL11
17
Shigellosis 36
12.41 TNF TLR4 IL1B CXCL8
18
Folate Metabolism 1
Show member pathways
 12.41 TNF PLG IL6 IL1B CRP
19
Salmonella infection (KEGG) 36
12.4 TNF TLR4 TLR2 IL6 IL1B CXCL8
20
Toll Comparative Pathway 63
Show member pathways
 12.39 TNF TLR4 IL6 IL1B CXCL8
21
Pathogenic Escherichia coli infection 36
12.35 TNF TLR4 IL6 IL1B CXCL8
22
Toxoplasmosis 36
Show member pathways
 12.35 TNF TLR4 TLR2 IL1B IL10 CD40LG
23
Diseases associated with the TLR signaling cascade 65
Show member pathways
 12.34 TNF TLR4 TLR2 IL6 CXCL8
24
NOD-like receptor signaling pathway 36
12.32 TNF TLR4 IL6 IL1B CXCL8
25
Tuberculosis 36
12.32 TNF TLR4 TLR2 IL6 IL1B IL10
26
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.31 TNF IL6 IL1B IL10 CXCL8
27
C-type lectin receptor signaling pathway 36
Show member pathways
 12.26 TNF IL6 IL1B IL10
28
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.26 TNF IL6 IL1B IL10 CXCL8
29
Colorectal Cancer Metastasis 63
12.24 TNF TLR4 TLR2 IL6
30
Bacterial infections in CF airways 22
Show member pathways
 12.17 TNF TLR4 TLR2 IL6 IL1B CXCL8
31
Spinal Cord Injury 1
12.1 TNF TLR4 IL6 IL1B CXCL8
32
IL-17 Family Signaling Pathways 64
Show member pathways
 12.09 TNF TLR2 MUC5B MUC5AC IL6 IL1B
33
Yersinia infection 36
12.07 TNF TLR4 IL6 IL1B IL10 CXCL8
34
Hematopoietic Stem Cells and Lineage-specific Markers 64
12.06 TNF IL6 IL10 CD79A
35
NF-kappa B signaling pathway 36
12.03 TNF TLR4 IL1B CXCL8 CD40LG
36
Interleukin-4 and 13 signaling 65
12.03 TNF IL6 IL1B IL10 CXCL8 CCL11
37
AGE-RAGE signaling pathway in diabetic complications 36
11.99 TNF IL6 IL1B CXCL8
38
IL27-mediated signaling events 1
Show member pathways
 11.98 TNF TLR4 TLR2 IL6 IL1B IL10
39
Th17 Differentiation 64
Show member pathways
 11.95 TLR4 TLR2 IL6 IL1B
40
Rheumatoid arthritis 36
11.9 TNF TLR4 TLR2 IL6 IL1B CXCL8
41
Dendritic Cells Developmental Lineage Pathway 64
11.84 TNF IL6 IL1B IL10
42
Innate Lymphoid Cells Differentiation 64
11.81 TNF IL1B IL10
43
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.78 TNF CXCL8 CD40LG
44
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.74 TNF IL6 IL1B CXCL8 CD40LG
45
Pertussis 36
11.73 TNF TLR4 IL6 IL1B IL10 CXCL8
46
IL4-mediated signaling events 1
11.7 IL10 CD40LG CCL11
47
MSP-RON Signaling 63
11.62 TNF TLR4 TLR2 IL1B
48
Interleukin-10 signaling 65
11.61 TNF IL6 IL1B IL10 CXCL8
49
Lung fibrosis 1
11.6 TNF MUC5B IL6 IL1B CXCL8 CCL11
50
amb2 Integrin signaling 1
11.57 TNF PLG IL6
Sources

GO Terms for Otitis Media

About this section

Cellular components related to Otitis Media according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TNF RNASE3 PLG MUC5B MUC5AC MBL2
2 cell surface GO:0009986 9.63 TNF TLR4 TLR2 PLG MBL2 CD40LG
3 extracellular space GO:0005615 9.47 TNF RNASE3 PLG MUC5B MUC5AC MBL2

Biological processes related to Otitis Media according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.11 TNF TLR4 TLR2 IL6 IL1B CRP
2 negative regulation of cell proliferation GO:0008285 10.08 TLR2 PLG IL6 IL1B IL10 CXCL8
3 defense response to bacterium GO:0042742 10.04 TNF TLR4 RNASE3 MBL2 IL10
4 cytokine-mediated signaling pathway GO:0019221 10 TNF IL6 IL1B IL10 CXCL8 CCL11
5 response to lipopolysaccharide GO:0032496 9.99 TLR4 TLR2 IL1B IL10
6 positive regulation of DNA-binding transcription factor activity GO:0051091 9.94 TNF IL6 IL1B IL10
7 neutrophil chemotaxis GO:0030593 9.89 IL1B CXCL8 CCL11
8 B cell differentiation GO:0030183 9.89 IL10 CD79A CD40LG
9 positive regulation of inflammatory response GO:0050729 9.89 TNF TLR4 TLR2 IL1B
10 response to glucocorticoid GO:0051384 9.88 TNF IL6 IL10
11 cellular response to lipopolysaccharide GO:0071222 9.88 TNF TLR4 IL6 IL1B IL10 CXCL8
12 positive regulation of T cell proliferation GO:0042102 9.87 IL6 IL1B CD40LG
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.86 TNF TLR4 TLR2 IL1B
14 positive regulation of phagocytosis GO:0050766 9.85 TNF MBL2 IL1B
15 positive regulation of interferon-gamma production GO:0032729 9.85 TNF TLR4 IL1B
16 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF TLR4 IL1B
17 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 TNF TLR4 TLR2 IL6 IL1B CD40LG
18 acute-phase response GO:0006953 9.84 MBL2 IL6 CRP
19 B cell proliferation GO:0042100 9.84 IL10 CD79A CD40LG
20 negative regulation of interleukin-6 production GO:0032715 9.83 TNF TLR4 IL10
21 positive regulation of JAK-STAT cascade GO:0046427 9.82 TNF IL6 IL10
22 positive regulation of interleukin-6 secretion GO:2000778 9.8 TNF TLR4 TLR2 IL1B
23 positive regulation of interleukin-12 production GO:0032735 9.79 TLR4 TLR2 CD40LG
24 positive regulation of interleukin-10 production GO:0032733 9.79 TLR4 TLR2 CD40LG
25 lipopolysaccharide-mediated signaling pathway GO:0031663 9.78 TNF TLR4 TLR2 IL1B
26 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.77 TNF TLR4 IL6
27 positive regulation of glial cell proliferation GO:0060252 9.76 TNF IL6 IL1B
28 positive regulation of interleukin-8 production GO:0032757 9.76 TNF TLR4 TLR2 IL1B
29 positive regulation of interleukin-8 secretion GO:2000484 9.75 TNF TLR4 TLR2
30 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.74 TNF IL1B IL10
31 negative regulation of neurogenesis GO:0050768 9.73 TNF IL6 IL1B CCL11
32 positive regulation of neuroinflammatory response GO:0150078 9.72 TNF IL6 IL1B
33 cellular response to lipoteichoic acid GO:0071223 9.71 TLR4 TLR2
34 positive regulation of MHC class II biosynthetic process GO:0045348 9.71 TLR4 IL10
35 opsonization GO:0008228 9.71 MBL2 CRP
36 response to molecule of bacterial origin GO:0002237 9.71 TLR2 IL10 CXCL8
37 regulation of establishment of endothelial barrier GO:1903140 9.7 TNF IL1B
38 endothelial cell apoptotic process GO:0072577 9.7 TNF IL10
39 negative regulation of cytokine production involved in immune response GO:0002719 9.69 TNF IL10
40 regulation of immunoglobulin secretion GO:0051023 9.69 TNF CD40LG
41 negative regulation of lipid storage GO:0010888 9.69 TNF IL6 CRP
42 positive regulation of fever generation GO:0031622 9.68 TNF IL1B
43 negative regulation of cytokine secretion involved in immune response GO:0002740 9.68 TNF IL10
44 sequestering of triglyceride GO:0030730 9.67 TNF IL1B
45 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.65 TNF IL1B
46 receptor biosynthetic process GO:0032800 9.65 TNF IL10
47 positive regulation of interleukin-6 production GO:0032755 9.65 TNF TLR4 TLR2 IL6 IL1B
48 positive regulation of matrix metallopeptidase secretion GO:1904466 9.63 TLR4 TLR2
49 defense response to Gram-positive bacterium GO:0050830 9.63 TNF TLR2 RNASE3 MBL2 IL6 CRP
50 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 9.62 TLR4 TLR2

Molecular functions related to Otitis Media according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 TNF IL6 IL1B IL10 CXCL8 CD40LG
2 lipopolysaccharide receptor activity GO:0001875 9.16 TLR4 TLR2
3 lipopolysaccharide binding GO:0001530 9.13 TLR4 TLR2 RNASE3
Sources

Sources for Otitis Media

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....